effect of simple zofa (hyssopus officinalis) syrup on persistant asthma

: A randomized, tripple blind, controlled, clinical trial effect of simple zofa (hyssopus officinalis) syrup on persistant asthma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110811007297N5

Enrollment

Registered

2018-04-04

Start date

2017-10-23

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

persistent asthma. Predominantly allergic asthma

Interventions

Intervention 1: Intervention group: En Intervention group patients will consume oral intervention drug (hyssop syrup) twice a day( fasting and bed time with 6.5 gram hyssop in each time) for 4 weeks(

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: older than 18 years old patients confirm of disease by internist. diagnosis criteria: acording to NAEP EPR3 criteria for persistant asthma disease: FEV1: 60-80%

Exclusion criteria

Exclusion criteria: history of allergy to plant of mint family dissatisfaction of treatment in each stage side effect development through treatment theophylline cosumption diabetic patients convulsion history pregnant patients patienta that need to hospitalize Exacerbation at beginning of study smokers diability in statement of symptom intensity

Design outcomes

Primary

Measure	Time frame
Spirometry indicator: FEV1 and FEV1 /FVC. Timepoint: at the first of the study(before intervention) and 4 weeks after intervention. Method of measurement: spirometry set.;Asthma treatment investigation score(The Expert Panel Report 3 (EPR 3)). Timepoint: at the first of the study(before intervention) and 4 weeks after intervention. Method of measurement: asthma treatment investigation questionnaire (The Expert Panel Report 3 (EPR 3)).;Asthma control test(ACT) score. Timepoint: at the first of the study(before intervention) , 4 weeks and 8 week after intervention. Method of measurement: asthma control test questionnaire(ACT).	—

Measure

Time frame

Spirometry indicator: FEV1 and FEV1 /FVC. Timepoint: at the first of the study(before intervention) and 4 weeks after intervention. Method of measurement: spirometry set.;Asthma treatment investigation score(The Expert Panel Report 3 (EPR 3)). Timepoint: at the first of the study(before intervention) and 4 weeks after intervention. Method of measurement: asthma treatment investigation questionnaire (The Expert Panel Report 3 (EPR 3)).;Asthma control test(ACT) score. Timepoint: at the first of the study(before intervention) , 4 weeks and 8 week after intervention. Method of measurement: asthma control test questionnaire(ACT).

—

Secondary

Measure	Time frame
Wheezing intensity determination. Timepoint: At the first of the study(before intervention) and 4 weeks after intervention. Method of measurement: History and physical exam with stethoscope.;Lung dystemperament. Timepoint: At the first of the study(before intervention) and 4 weeks after intervention. Method of measurement: Primary questionnaire of lung dystemperament investigation in terms of warm and cold and primary questionnaire of lung dystemperament investigation in terms of wet and drought.	—

Measure

Time frame

Wheezing intensity determination. Timepoint: At the first of the study(before intervention) and 4 weeks after intervention. Method of measurement: History and physical exam with stethoscope.;Lung dystemperament. Timepoint: At the first of the study(before intervention) and 4 weeks after intervention. Method of measurement: Primary questionnaire of lung dystemperament investigation in terms of warm and cold and primary questionnaire of lung dystemperament investigation in terms of wet and drought.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Amir Mohammad Jaladat

Shiraz University of Medical Sciences

drjaladat@gmail.com+98 71 3234 5145

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026